[On pharmaceutical microbiology in the development of external drugs using the example of alpha,alpha-dicyclopentylacetic acid-diethylamino-ethylester-bromoctylate (Ug 767)].
D000327:Adsorption; D000362:Agar; D000535:Aluminum / Q000494:pharmacology; D004344:Drug Incompatibility; D004357:Drug Synergism; D004573:Electrolytes / Q000494:pharmacology; D005782:Gels / Q000494:pharmacology; D006582:Hexachlorophene / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D005779:Immunodiffusion; D010592:Pharmaceutic Aids; D014677:Pharmaceutical Vehicles; D011208:Powders; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology; D012459:Salicylates; D012997:Solvents; D013210:Staphylococcus / Q000187:drug effects*; D013501:Surface-Active Agents / Q000494:pharmacology
D004573:Electrolytes; D005782:Gels; D010592:Pharmaceutic Aids; D014677:Pharmaceutical Vehicles; D011208:Powders; D000644:Quaternary Ammonium Compounds; D011804:Quinolines; D012459:Salicylates; D012997:Solvents; D013501:Surface-Active Agents; D000362:Agar; D000535:Aluminum; D006582:Hexachlorophene
Zur pharmazeutischen Mikrobiologie bei der Entwicklung von Externa am Beispiel des alpha,alpha-Dicyclopentylessigsäure-diäthylamino-äthylester-bromoctylats (Ug 767)